ABSTRACT
INTRODUCTION
Spontaneous bacterial peritonitis (SBP) is the commonest complication among patients with liver cirrhosis.
(1) SBP can lead to decompensation of liver cirrhosis, acute-on-chronic liver failure (ACLF) with fourfold increased risk of short-term mortality, early readmission and increased healthcare burden. (2, 3) Despite early recognition and treatment according to current guidelines, its 90-day mortality rate remained high, ranging from 43.9% to 79.4%. (4) (5) (6) This poor outcome is largely attributed to the emergence of multidrug-resistant organisms (MDROs) and Gram-positive organisms in patients with SBP.
The 'leaky gut' theory suggests that SBP is a complication of the translocation of enteric bacteria into ascetic fluid. The three main mechanisms that support this theory among patients with advanced cirrhosis are increased gut permeability, gut dysbiosis and reduced peritoneal immunoglobulin concentration. (7, 8) Increased gut permeability occurs as a result of portal hypertension in advance cirrhosis, leading to gut oedema and subsequent loosening of tight junctions, (9) (10) (11) particularly among patients with ascites. (12) Gut dysbiosis is well reported among patients with cirrhosis. (13) In particular, cirrhotic patients receiving quinolone
prophylaxis have been associated with the emergence of MDROs in SBP. (14) Together with increased gut permeability and gut dysbiosis, patients with advanced cirrhosis were also found to have reduced peritoneal immunoglobulins and impaired opsonisation of translocated enteric organisms, thus leading to an increased risk of SBP in these patients. (15) (16) (17) The rising trend of MDROs among patients with SBP is a growing concern. (18) Recognising the global threat of antimicrobial resistance, the World Health Organization (WHO) has endorsed a global action plan to counter antimicrobial resistance and ensure the continuity of effective treatment options for infectious disease. (19) The emergence of MDROs reduces the efficacy of empirical antibiotic treatment for SBP, resulting in prolonged hospitalisation as well as increased healthcare utilisation, morbidity and mortality among patients with SBP. This change in the epidemiology and resistance pattern of the microorganisms causing SBP was attributed to the widespread use of broad-spectrum antibiotics, primary prophylaxis for SBP and increasing instrumentation for cirrhosis patients. (20) However, resistance patterns of micro-organisms in SBP vary geographically. While the use of broader spectrum antibiotics for SBP could improve treatment response in a region with a high prevalence of MDROs, the same practice could potentially promote the emergence of MDROs among regions where their prevalence is low. Thus, understanding local resistance patterns is essential in order to tailor our empirical treatment to SBP in Singapore.
Identifying the outcome predictors of SBP is also important, not only in identifying patients who are more likely to benefit from more aggressive empirical treatment, but also to enhance our understanding of the pathogenesis of SBP. Reported predictors of poor outcome among SBP include MDROs, septic shock, poor liver reserve and nosocomial SBP (N-SBP). (3, 5, (21) (22) (23) These patients may benefit from broad-spectrum antibiotics as an empirical treatment for SBP.
To date, N-SBP remains an under-recognised entity in Singapore. The primary aim of this study was to describe the clinical outcomes of SBP in Singapore, while the secondary aim was to determine the prevalence of N-SBP in Singapore.
METHODS
This study was conducted at Changi General Hospital, a 1,000-bed teaching hospital serving a population of 1.3 million from the east and north-east regions of Singapore. We conducted a retrospective observational study of all SBP diagnosed among patients with liver cirrhosis between January 2014 and December 2017.
Patients were identified using electronic medical records using the procedure code for paracentesis and ICD-10 (International Classification of Diseases, 10th revision) code for liver cirrhosis. All adult patients (age ≥ 18 years) with a diagnosis of liver cirrhosis and SBP who underwent paracentesis were consecutively included. Data on all patients' baseline characteristics and outcomes were reviewed by the investigator using electronic medical records. Patients were excluded if there was secondary peritonitis, malignant ascites or lack of data on primary outcomes. All patients were followed up for a minimum of six months from the date of hospitalisation. The study protocol was approved by our institutional review board
Paracentesis was performed for all cirrhotic patients who were hospitalised for decompensation with clinical suspicion of SBP and refractory ascites. All paracenteses were performed using sterile technique. The ascitic fluid collected was sent for fluid analysis, which included polymorphonuclear leucocytes (PMN) counting. An additional 10 mL of ascitic fluid was collected and inoculated into aerobic and anaerobic blood culture bottles for seven days.
Positive cultures identified would be tested with the antibiotic susceptibility test using the VITEK® 2 compact system and minimal inhibitory concentration method. An empirical antibiotic was initiated upon the diagnosis of SBP according to international guidelines. (2) Patients with community-acquired SBP (C-SBP) received intravenous ceftriaxone, while patients with N-SBP received intravenous piperacillin/tazobactam. Intravenous albumin was administrated to all patients diagnosed with SBP, as per guideline. (24) We subsequently studied the clinical outcome of SBP, which included 30-day and 90-day mortality, and factors associated with these outcomes.
SBP was defined as PMN ≥ 250 cells/mm 3 in the ascites fluid or positive culture from the ascites fluid. SBP that was diagnosed more than 48 hours after hospitalisation was defined as N-SBP. SBP that was diagnosed within 48 hours after hospitalisation without recent hospitalisation in the preceding three months was defined as C-SBP. (25) Cirrhosis was defined based on clinical, biochemical, radiological and/or histological findings. The severity of liver cirrhosis was assessed using the Child-Pugh score and the Model for End-stage Liver Disease score with sodium (MELD-Na) and without sodium (MELD) at the point of diagnosis of SBP.
The presence of shock upon hospitalisation was defined as systolic blood pressure < 90 mmHg and mean arterial pressure < 65 mmHg in the presence of SBP. Systemic inflammatory response syndrome (SIRS) was defined as fulfilling two or more of the following criteria: fever > 38°C or < 36°C, heart rate > 90 beats per minute, respiratory rate > 20 breaths per minute and abnormal white cell count (> 12,000/µL or < 4,000/µL). Presence of ACLF was defined based on the CANONIC study definition. (26) Extended-spectrum beta-lactamase-producing (ESBLproducing) organisms were defined as micro-organisms with resistance to extended-spectrum (third-generation) cephalosporin and monobactams. MDROs were defined as micro-organisms with resistance to at least one agent in three or more anti-microbial categories. (27) All analysis was performed with SPSS Statistics version 21.0 (IBM Corp, Armonk, NY, USA). Continuous variables were computed using Student's t-test or Mann-Whitney U test, and categorical variables were computed using chi-square test or Fisher's exact test. Univariate analysis was performed to identify factors associated with study outcomes. All covariates with p < 0.10 on univariate analysis were retained and included in multivariate analysis. The data were censored at last follow-up, liver transplantation or death. A p-value < 0.05 was indicative of statistical significance.
RESULTS
A total of 33 patients with 39 episodes of SBP were studied among 645 patients with cirrhosis.
Therefore, the incidence of SBP was 5.1%. Of the patients with SBP, 23 (69.7%) were male with a mean age of 64.5 ± 10.9 years. The commonest aetiology of cirrhosis was chronic hepatitis B (27.3%) followed by chronic hepatitis C (24.2%), non-alcoholic steatohepatitis of the episodes of SBP, respectively. ESBL-producing organisms were more commonly seen in N-SBP compared to C-SBP cases (83.3% vs. 16.7%; p = 0.002) (Fig. 1) . All cases of multidrug resistance occurred in the N-SBP group. Resistance to third-generation cephalosporin and quinolones was observed in 12.8% and 10.3% of cases, respectively. The trend of ESBL-producing organisms and MDROs remained low and stable from 2014 to 2017 (Fig. 2) . The Gram-positive organism was found in 3 (7.7%) out of 39 SBP cases (2 Streptococcus sp. and 1 Enterococcus sp.).
The prevalence of N-SBP in our cohort was 10 (25.6%) out of 39 cases. The baseline demographics were similar between patients with C-SBP and N-SBP with respect to age, gender, aetiology of cirrhosis, severity of cirrhosis (Child-Pugh, MELD and MELD-Na scores), cirrhosis-related complications (refractory ascites, previous variceal bleeding and hepatic encephalopathy), proton-pump inhibitor usage and beta-blocker usage. Compared to C-SBP, N-SBP was associated with previous antibiotic use in the past three months (44.8% vs. 90.0%; p = 0.014) and prolonged hospitalisation (11.7 ± 9.2 days vs. 38.3 ± 31.6 days; p = 0.011) (Table II) . (28) (29) (30) The rising trend of multidrug resistance worldwide continues to threaten the sustainability of effective treatments for common infections such as SBP. Because early initiation of appropriate empirical therapy improves survival in N-SBP, and the prevalence of N-SBP varies geographically, ranging from 30.8% in Korea to 93.3% in France, such empirical therapy must be guided by knowledge of the local antibiotic resistance profile. (5, 7, 25, 28, 29, (31) (32) (33) (34) (35) In the present study, we reported a relatively lower prevalence (25.6%) of N-SBP in Singapore. With the low prevalence of resistant organisms among cirrhotic patients with SBP, the current empirical antibiotic recommendations of using ceftriaxone for C-SBP and piperacillin/tazobactam for N-SBP are reasonable options for Singapore. (36) To our knowledge, no prior study has evaluated the epidemiology and outcome predictors of N-SBP locally. Judicious use of antibiotics is crucial to prevent the rise of ESBL-producing organisms and MDROs in our cohort before we pass the critical point.
We found that N-SBP was strongly associated with ESBL-producing organisms and longer hospitalisation as compared to C-SBP (Table II) . These findings were consistent with earlier studies from European and Korean cohorts, in which a high prevalence of resistant organisms was observed. (5, 22, (37) (38) (39) (40) Table V shows our review of the existing literature on the outcomes of N-SBP. In our cohort, in contrast to the earlier studies, N-SBP was not associated with higher 30-day mortality (Table III) . This may be due to three reasons. First, there was a lower proportion of Child-Pugh Class C cirrhotic patients in our cohort compared to the earlier studies. Second, there was a lower prevalence of ESBL-producing organisms and MDROs in our cohort. Lastly, all our N-SBP patients received adequate empirical coverage (piperacillin/tazobactam). This finding suggests that the administration of appropriate antibiotics following local resistant patterns can improve short-term survival for N-SBP patients. A MELD score > 20 and the presence of N-SBP were found to be predictors for 90-day mortality in SBP. A MELD score > 20 was also found to predict higher 30-day mortality. The MELD score cutoff as a predictor of mortality in SBP was consistent with findings in the published literature. (23, 41) This suggests that patients with poorer liver reserve are either more likely to develop SBP or to decompensate following the occurrence of SBP. A MELD score > 20 could be used as the threshold for initiating more aggressive treatment or closer monitoring among SBP patients. On the other hand, N-SBP was associated with higher 90-day mortality and shorter median survival (Table IV) . The high mortality rate among N-SBP cases could be related to gut dysbiosis among advanced cirrhosis patients. (14) Nevertheless, the question of whether the alteration of gut microbiome observed in N-SBP was the consequence of the disease itself or could potentially lead to more advanced disease remains unanswered.
In our study, the use of NSBBs had a protective effect, reducing 90-day mortality among SBP patients (Table IV) . The initial concern about NSBB usage among patients with SBP arose when Mandorfer et al reported a higher risk of hepatorenal syndrome and worse transplant-free survival among 182 SBP patients receiving NSBBs. (42) In contrast, more recent studies showed that NSBBs are associated with the reduction of mortality among patients with SBP in the Danish and CANONIC cohorts. (43, 44) These findings suggest that although NSBBs are not harmful in SBP, yet the indiscriminate cessation of NSBB usage among all patients with SBP could be harmful. The decision on NSBB usage should be individualised, and a high dose of NSBB (> 160 mg/day) should be avoided among patients with SBP.
The widespread use of quinolone for primary prophylaxis of SBP has been controversial, as it may have contributed to the rising incidence of Gram-positive cocci among SBP cases. Our Gram-positive cocci rate was lower than those in published series. (34) Due to the limitation of measuring ascetic fluid albumin below 20 g/L, primary prophylaxis of SBP is rarely practised in our institution. Such a practice is likely to be the reason behind an overall low prevalence of Gram-positive organism in our cohort.
We acknowledge that this study had its limitations. First, it had a retrospective and nonrandomised design. We tried to address this limitation by adjusting all findings to account for differences in baseline characteristics and potential confounders in multivariate analysis.
Second, our results on the demographics of cirrhosis aetiologies and the antimicrobial resistant pattern were derived from a single institution, thus might not be generalisable to another centre.
Third, the incidence of SBP may be underdiagnosed, because subjects with clinical suspicion of SBP alone were excluded from this study. Lastly, our sample size is small. A future prospective multicentre study would be ideal to verify our findings.
In conclusion, the prevalence of resistant organisms among N-SBP is low in our population. Early recognition and judicious use of antibiotics can improve survival in N-SBP.
A MELD score > 20 and the presence of N-SBP are predictors of poor outcome among SBP,
while the use of NSBBs should be individualised. Our study suggests that the current recommendation for empirical treatment of SBP is appropriate in Singapore. 
